HCID 18373519, compound → HCID 18373497, compound

HRID 2301568Notes

Reaction equation

HRID 2301568 reaction equation
[C:1]([O:5][C:6]([N:8]1[CH2:13][CH2:12][CH:11]([CH2:14][NH:15][S:16]([C:19]2[C:24]([Cl:25])=[CH:23][CH:22]=[C:21]([N+:26]([O-])=O)[C:20]=2[OH:29])(=[O:18])=[O:17])[CH2:10][CH2:9]1)=[O:7])([CH3:4])([CH3:3])[CH3:2].[H][H]>[Pd]>[C:1]([O:5][C:6]([N:8]1[CH2:13][CH2:12][CH:11]([CH2:14][NH:15][S:16]([C:19]2[C:24]([Cl:25])=[CH:23][CH:22]=[C:21]([NH2:26])[C:20]=2[OH:29])(=[O:17])=[O:18])[CH2:10][CH2:9]1)=[O:7])([CH3:4])([CH3:2])[CH3:3]

Participants

4

Reactant 2

HCID 18373519HCID 18373519, compoundHCID 178418361HCID 178418361, compound

Product 1

HCID 18373497HCID 18373497, compound

Reagents, catalysts & solvents 1

HCID 23938PalladiumCatalyst

Procedure

Following the general hydrogenation procedure outlined in example 15, N-[(1-tert-butoxycarbonylpiperidin-4-yl)methyl]-6-chloro-2-hydroxy-3-nitrobenzenesulfonamide (480 mg, 1.07 mmol) was reduced with hydrogen and 10% Pd/C (240 mg). The crude product (460 mg) was carried on to the next step without purification. 1H NMR (MeOD-d4): δ 6.86 (m, 2H), 4.00 (d, 2H), 2.83 (m, 2H), 2.78 (m, 2H), 1.60 (m, 3 H), 1.44 (s, 9H), 1.00 (m, 2H).

Workup

  1. customThe crude product (460 mg) was carried on to the next step without purification

Sources & evidence

ORD record
ord-8418516cc4cc41de836b09733c03a246
Source dataset
uspto-grants-2002_12
Patent number
US06500863B1

Reaction notes

Loading…